SG Americas Securities’s Inari Medical, Inc. Common Stock NARI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-15,144
Closed -$625K 3719
2024
Q3
$625K Buy
+15,144
New +$727K ﹤0.01% 1491
2024
Q2
Sell
-11,302
Closed -$542K 3399
2024
Q1
$542K Sell
11,302
-10,444
-48% -$558K ﹤0.01% 1388
2023
Q4
$1.41M Buy
21,746
+7,036
+48% +$424K 0.01% 848
2023
Q3
$962K Buy
+14,710
New +$925K 0.01% 1301
2023
Q2
Sell
-14,857
Closed -$917K 3325
2023
Q1
$917K Buy
14,857
+670
+5% +$40.2K 0.01% 1198
2022
Q4
$902K Buy
14,187
+7,599
+115% +$551K 0.01% 1043
2022
Q3
$479K Sell
6,588
-12,334
-65% -$918K 0.01% 1587
2022
Q2
$1.29M Buy
+18,922
New +$1.36M 0.01% 1085
2022
Q1
Sell
-4,958
Closed -$453K 3544
2021
Q4
$453K Sell
4,958
-8,926
-64% -$765K ﹤0.01% 2220
2021
Q3
$1.13M Buy
13,884
+7,033
+103% +$591K 0.01% 1802
2021
Q2
$639K Sell
6,851
-1,490
-18% -$144K ﹤0.01% 1829
2021
Q1
$892K Buy
+8,341
New +$865K ﹤0.01% 1632

Other funds holding NARI

SG Americas Securities's NARI Position: Q4 2024 in Review

SG Americas Securities sold out of Inari Medical, Inc. Common Stock (NARI) in Q4 2024, closing a stake of 15,144 shares — an estimated $625K sold.

SG Americas Securities first reported a position in NARI in Q1 2021 and held it in 12 quarters. The position peaked at $1.41M in Q4 2023. 258 funds tracked by Wall St. Rank hold NARI as of Q4 2024.

  • SG Americas Securities reported no remaining Inari Medical, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • SG Americas Securities sold 15,144 Inari Medical, Inc. Common Stock shares in Q4 2024, an estimated $625K.
  • SG Americas Securities first reported a position in Inari Medical, Inc. Common Stock in Q1 2021 and held it in 12 quarters.
  • SG Americas Securities's Inari Medical, Inc. Common Stock position peaked at $1.41M in Q4 2023.
  • 258 funds tracked by Wall St. Rank held Inari Medical, Inc. Common Stock as of Q4 2024.

Based on SG Americas Securities's 13F filing for Q4 2024, filed 17 Jan 2025.